{"nctId":"NCT01652716","briefTitle":"Efficacy and Safety of Exenatide Once Weekly Suspension in Subjects With Type 2 Diabetes","startDateStruct":{"date":"2013-01"},"conditions":["Diabetes Mellitus, Type 2"],"count":377,"armGroups":[{"label":"Exenatide once weekly suspension","type":"EXPERIMENTAL","interventionNames":["Drug: Exenatide once weekly suspension"]},{"label":"Exenatide twice daily (BID)","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Exenatide twice daily"]}],"interventions":[{"name":"Exenatide once weekly suspension","otherNames":[]},{"name":"Exenatide twice daily","otherNames":["Byetta"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* At least 18 years old\n* Diagnosed with type 2 diabetes mellitus\n* HbA1c 7.1 to 11%, inclusive, at screening\n* Fasting plasma glucose \\<280 mg/dL (15.5 mmol/L)\n* Body mass index (BMI) \\<=45 kg/m2, inclusive, at screening\n* Treated with diet and exercise or a stable regimen of metformin, sulfonylurea, pioglitazone or any 2 of these agents\n\nExclusion Criteria:\n\n* History of pancreatitis or triglycerides \\>=500 mg/dL\n* Medullary carcinoma or multiple endocrine neoplasia (MEN2) or a family history of either\n* Active cardiovascular disease\n* Presence of congestive heart failure\n* Liver disease\n* History of severe gastrointestinal diseases\n* Repeated severe hypoglycemia within the last 6 months\n* Any previous use of exenatide or other glucagon-like peptide-1 (GLP-1 ) analog\n* Dipeptidyl peptidase-4 (DPP-4) inhibitor use in the last 3 months","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Change in HbA1c (Glycosylated Hemoglobin) From Baseline to Week 28","description":"The primary objective of this study was to compare the effect on glycemic control (HbA1c) of exenatide suspension administered once weekly to that achieved by exenatide administered twice daily for 28 weeks in subjects with type 2 diabetes mellitus.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.39","spread":"0.0930"},{"groupId":"OG001","value":"-1.02","spread":"0.1147"}]}]}]},{"type":"SECONDARY","title":"Percentage of Subjects Achieving HbA1c <7% at Week 28","description":"Percentage of subjects achieving HbA1c \\<7% at Week 28/Study Termination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"3.9","spread":null},{"groupId":"OG001","value":"1.4","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"95.2","spread":null},{"groupId":"OG001","value":"98.6","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.3","spread":null},{"groupId":"OG001","value":"43.2","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"49.8","spread":null},{"groupId":"OG001","value":"56.8","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.9","spread":null},{"groupId":"OG001","value":"0","spread":null}]}]}]},{"type":"SECONDARY","title":"Change in Fasting Plasma Glucose Concentrations From Baseline to Week 28","description":"Change in fasting plasma glucose concentrations from baseline to Week 28/Study Termination","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-32.7","spread":"3.906"},{"groupId":"OG001","value":"-22.5","spread":"4.917"}]}]}]},{"type":"SECONDARY","title":"Change in Body Weight (kg) From Baseline to Week 28","description":"Change in body weight (kg) from baseline to Week 28/Study Termination.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-1.49","spread":"0.2842"},{"groupId":"OG001","value":"-1.89","spread":"0.3640"}]}]}]},{"type":"SECONDARY","title":"Change in 2-hour Postprandial Glucose Concentrations From Baseline to Week 16","description":"Change in 2-hour postprandial glucose concentrations from baseline to Week 16.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"-87.00","spread":"12.8374"},{"groupId":"OG001","value":"-113.74","spread":"14.8042"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":12,"n":229},"commonTop":["Nausea","Injection Site Nodule","Diarrhoea","Headache","Upper Respiratory Tract Infection"]}}}